Montelukast Sandoz (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from binding. This inhibition stops leukotriene‑driven bronchoconstriction, mucus secretion, and inflammatory cell recruitment, thereby decreasing airway narrowing and allergic inflammation.

The dosage of Montelukast Sandoz is determined by the prescribing clinician based on the patient’s age, condition, and response to therapy. Standard dosing regimens exist for different indications, but the exact amount and frequency must be set by a qualified health‑care professional.

Safety data for Montelukast in pregnancy and lactation are limited, and the product does not have a definitive pregnancy category. Prescribers should weigh potential benefits against possible risks and consider alternative treatments when appropriate. Breastfeeding mothers should consult their physician before use.

To place an order, submit an enquiry on the Montelukast Sandoz product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids for asthma maintenance. Compared with inhaled steroids, it provides a convenient once‑daily tablet but may have a different side‑effect profile, especially regarding neuropsychiatric events. Choice depends on individual patient factors and physician judgment.

Montelukast Sandoz tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or other humid environments.

Montelukast Sandoz is taken orally as a tablet, usually once daily in the evening. The tablet should be swallowed whole with water and can be taken with or without food. Patients should follow the specific timing instructions provided by their prescriber.

Serious adverse events include severe allergic reactions (e.g., angioedema, anaphylaxis), neuropsychiatric disturbances such as mood changes, depression or suicidal thoughts, and rare skin conditions like Stevens‑Johnson syndrome. Any sudden or severe symptoms should prompt immediate medical evaluation.

Montelukast is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised for patients with severe hepatic impairment, and it should be used only after careful risk‑benefit assessment in pregnant or breastfeeding women. Children under the approved age for the specific formulation should not receive the product.